Amyotrophic Lateral Sclerosis (ALS) Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Amyotrophic Lateral Sclerosis (ALS) Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Report Format: PDF+Excel | Report ID: SR112025A6459

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Amyotrophic Lateral Sclerosis - Introduction
4.1 Overview
4.2 Epidemiology (2019-2024) and Forecast (2025-2035)
4.3 Market Overview (2019-2024) and Forecast (2025-2035)
4.4 Competitive Intelligence

5 Amyotrophic Lateral Sclerosis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Amyotrophic Lateral Sclerosis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2019-2024)
7.2.2 Epidemiology Forecast (2025-2035)
7.2.3 Epidemiology by Age (2019-2035)
7.2.4 Epidemiology by Gender (2019-2035)
7.2.5 Epidemiology by Type (2019-2035)
7.2.6 Diagnosed Cases (2019-2035)
7.2.7 Patient Pool/Treated Cases (2019-2035)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2019-2024)
7.3.2 Epidemiology Forecast (2025-2035)
7.3.3 Epidemiology by Age (2019-2035)
7.3.4 Epidemiology by Gender (2019-2035)
7.3.5 Epidemiology by Type (2019-2035)
7.3.6 Diagnosed Cases (2019-2035)
7.3.7 Patient Pool/Treated Cases (2019-2035)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2019-2024)
7.4.2 Epidemiology Forecast (2025-2035)
7.4.3 Epidemiology by Age (2019-2035)
7.4.4 Epidemiology by Gender (2019-2035)
7.4.5 Epidemiology by Type (2019-2035)
7.4.6 Diagnosed Cases (2019-2035)
7.4.7 Patient Pool/Treated Cases (2019-2035)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2019-2024)
7.5.2 Epidemiology Forecast (2025-2035)
7.5.3 Epidemiology by Age (2019-2035)
7.5.4 Epidemiology by Gender (2019-2035)
7.5.5 Epidemiology by Type (2019-2035)
7.5.6 Diagnosed Cases (2019-2035)
7.5.7 Patient Pool/Treated Cases (2019-2035)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2019-2024)
7.6.2 Epidemiology Forecast (2025-2035)
7.6.3 Epidemiology by Age (2019-2035)
7.6.4 Epidemiology by Gender (2019-2035)
7.6.5 Epidemiology by Type (2019-2035)
7.6.6 Diagnosed Cases (2019-2035)
7.6.7 Patient Pool/Treated Cases (2019-2035)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2019-2024)
7.7.2 Epidemiology Forecast (2025-2035)
7.7.3 Epidemiology by Age (2019-2035)
7.7.4 Epidemiology by Gender (2019-2035)
7.7.5 Epidemiology by Type (2019-2035)
7.7.6 Diagnosed Cases (2019-2035)
7.7.7 Patient Pool/Treated Cases (2019-2035)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2019-2024)
7.8.2 Epidemiology Forecast (2025-2035)
7.8.3 Epidemiology by Age (2019-2035)
7.8.4 Epidemiology by Gender (2019-2035)
7.8.5 Epidemiology by Type (2019-2035)
7.8.6 Diagnosed Cases (2019-2035)
7.8.7 Patient Pool/Treated Cases (2019-2035)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2019-2024)
7.9.2 Epidemiology Forecast (2025-2035)
7.9.3 Epidemiology by Age (2019-2035)
7.9.4 Epidemiology by Gender (2019-2035)
7.9.5 Epidemiology by Type (2019-2035)
7.9.6 Diagnosed Cases (2019-2035)
7.9.7 Patient Pool/Treated Cases (2019-2035)

8 Amyotrophic Lateral Sclerosis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Amyotrophic Lateral Sclerosis Guidelines, Management and Treatment
8.2 Amyotrophic Lateral Sclerosis Treatment Algorithm

9 Amyotrophic Lateral Sclerosis - Unmet Needs

10 Amyotrophic Lateral Sclerosis - Key Endpoints of Treatment

11 Amyotrophic Lateral Sclerosis - Marketed Products
11.1 List of Amyotrophic Lateral Sclerosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Amyotrophic Lateral Sclerosis - Pipeline Drugs
12.1 List of Amyotrophic Lateral Sclerosis Pipeline Drugs Across the Top 7 Markets
12.1.1  Debamestrocel - BrainStorm Cell Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 VHB937 - Novartis Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Amyotrophic Lateral Sclerosis - Attribute Analysis of Key Marketed and Pipeline Drugs

 

14 Amyotrophic Lateral Sclerosis (ALS) – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Amyotrophic Lateral Sclerosis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1    Amyotrophic Lateral Sclerosis - Market Size
15.2.1.1 Market Size (2019-2024)
15.2.1.2 Market Forecast (2025-2035)
15.2.2    Amyotrophic Lateral Sclerosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2019-2024)
15.2.2.2 Market Forecast by Therapies (2025-2035)
15.3 Market Scenario - United States
15.3.1    Amyotrophic Lateral Sclerosis - Market Size
15.3.1.1 Market Size (2019-2024)
15.3.1.2 Market Forecast (2025-2035)
15.3.2    Amyotrophic Lateral Sclerosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2019-2024)
15.3.2.2 Market Forecast by Therapies (2025-2035)
15.3.3    Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1    Amyotrophic Lateral Sclerosis - Market Size
15.4.1.1 Market Size (2019-2024)
15.4.1.2 Market Forecast (2025-2035)
15.4.2    Amyotrophic Lateral Sclerosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2019-2024)
15.4.2.2 Market Forecast by Therapies (2025-2035)
15.4.3    Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1    Amyotrophic Lateral Sclerosis - Market Size
15.5.1.1 Market Size (2019-2024)
15.5.1.2 Market Forecast (2025-2035)
15.5.2    Amyotrophic Lateral Sclerosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2019-2024)
15.5.2.2 Market Forecast by Therapies (2025-2035)
15.5.3    Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1    Amyotrophic Lateral Sclerosis - Market Size
15.6.1.1 Market Size (2019-2024)
15.6.1.2 Market Forecast (2025-2035)
15.6.2    Amyotrophic Lateral Sclerosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2019-2024)
15.6.2.2 Market Forecast by Therapies (2025-2035)
15.6.3    Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1    Amyotrophic Lateral Sclerosis - Market Size
15.7.1.1 Market Size (2019-2024)
15.7.1.2 Market Forecast (2025-2035)
15.7.2    Amyotrophic Lateral Sclerosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2019-2024)
15.7.2.2 Market Forecast by Therapies (2025-2035)
15.7.3    Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1    Amyotrophic Lateral Sclerosis - Market Size
15.8.1.1 Market Size (2019-2024)
15.8.1.2 Market Forecast (2025-2035)
15.8.2    Amyotrophic Lateral Sclerosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2019-2024)
15.8.2.2 Market Forecast by Therapies (2025-2035)
15.8.3    Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1    Amyotrophic Lateral Sclerosis - Market Size
15.9.1.1 Market Size (2019-2024)
15.9.1.2 Market Forecast (2025-2035)
15.9.2    Amyotrophic Lateral Sclerosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2019-2024)
15.9.2.2 Market Forecast by Therapies (2025-2035)
15.9.3    Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview

16 Amyotrophic Lateral Sclerosis - Recent Events and Inputs From Key Opinion Leaders

17 Amyotrophic Lateral Sclerosis Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats

18 Amyotrophic Lateral Sclerosis (ALS) Market – Strategic Recommendations

19 Appendix

Amyotrophic Lateral Sclerosis (ALS) Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035
Purchase Options Year End
sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-201-971-6302

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials